StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$251.41+0.62 (+0.25%)

Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –

Biogen pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Biogen's pe ratio was 44.9× on Nov 11, 2026, against 16.6× a year earlier. Over the last 5 years it ranged from 10.8× to 44.9×, with a median of 20.2×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202644.9×+28.8
2025Dec 31, 202516.0×+2.2
2024Dec 31, 202413.8×−11.9
2023Dec 29, 202325.7×+11.6
2022Dec 30, 202214.1×−9.4
2021Dec 31, 202123.5×+15.4
2020Dec 31, 20208.1×−2.4
2019Dec 31, 201910.6×−8.9
2018Dec 31, 201819.5×−0.1
2017Dec 29, 201719.5×+3.5
2016Dec 30, 201616.0×−4.0
2015Dec 31, 201520.0×−12.1
2014Dec 31, 201432.1×−7.1
2013Dec 31, 201339.2×+10.2
2012Dec 31, 201229.0×+1.1
2011Dec 30, 201127.9×+7.6
2010Dec 31, 201020.3×+2.4
2009Dec 31, 200918.0×–

More Biogen figures

See a number that looks wrong?